Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan M Chinai

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oncoimmunology|September 26, 2015
HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 familiesMurali Janakiram, Jordan M Chinai, Aimin Zhao, et al.
Trends in Pharmacological Sciences|July 12, 2015
New immunotherapies targeting the PD-1 pathwayJordan M Chinai, Murali Janakiram, Fuxiang Chen, et al.
Journal of the American Chemical Society|April 9, 2011
Molecular recognition of insulin by a synthetic receptorJordan M Chinai, Alexander B Taylor, Lisa M Ryno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2016
HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational StatusHaiying Cheng, Murali Janakiram, Alain Borczuk, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 30, 2013
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionRuihua Zhao, Jordan M Chinai, Susan Buhl, et al.
Scientific Reports|July 27, 2016
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcomaPratistha Koirala, Michael E Roth, Jonathan Gill, et al.
Scientific Reports|August 18, 2016
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survivalPratistha Koirala, Michael E Roth, Jonathan Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Nature Communications|April 6, 2026
In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicityKyrellos E Ibrahim, Kepler S Mears, Peter M Allen, et al.
Science Immunology|July 10, 2021
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic targetYao Wei, Xiaoxin Ren, Phillip M Galbo, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncoimmunology|September 26, 2015
HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 familiesMurali Janakiram, Jordan M Chinai, Aimin Zhao, et al.
Trends in Pharmacological Sciences|July 12, 2015
New immunotherapies targeting the PD-1 pathwayJordan M Chinai, Murali Janakiram, Fuxiang Chen, et al.
Journal of the American Chemical Society|April 9, 2011
Molecular recognition of insulin by a synthetic receptorJordan M Chinai, Alexander B Taylor, Lisa M Ryno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2016
HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational StatusHaiying Cheng, Murali Janakiram, Alain Borczuk, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 30, 2013
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionRuihua Zhao, Jordan M Chinai, Susan Buhl, et al.
Scientific Reports|July 27, 2016
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcomaPratistha Koirala, Michael E Roth, Jonathan Gill, et al.
Scientific Reports|August 18, 2016
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survivalPratistha Koirala, Michael E Roth, Jonathan Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2015
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinMurali Janakiram, Jordan M Chinai, Susan Fineberg, et al.
Nature Communications|April 6, 2026
In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicityKyrellos E Ibrahim, Kepler S Mears, Peter M Allen, et al.
Science Immunology|July 10, 2021
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic targetYao Wei, Xiaoxin Ren, Phillip M Galbo, et al.
Pageof 2